Table 3.

Analysis of incidence of first primary cancers in RINT1 mutation–carrying families

Cancers observedaRINT1 vs. wild-typeRINT1 vs. population rates
Site groupbRINT1WTHR (95% CI)PSIR (carriers) (95% CI)P
All non-breast512,1171.67 (1.2–2.3)0.00092.23 (1.3–3.5)0.005
Gastrointestinal133632.51 (1.4–4.4)0.0012.46 (0.8–5.9)0.050
Female122512.89 (1.6–5.3)0.00077.90 (2.5–19)0.0008
Lynch syndrome183753.24 (1.9–5.7)4 × 10−53.66 (1.4–7.7)0.009
Lynch syndrome dx <60131913.79 (2.2–6.5)10−612.4 (3.7–30)0.012
Lynch syndrome spectrum308232.44 (1.5–3.9)0.00033.35 (1.7–6.0)0.005
Lynch syndrome spectrum dx <60224442.71 (1.8–4.0)4 × 10−710.9 (4.7–21)0.0003
All but Lynch syndrome331,7421.33 (0.8–1.8)0.121.52 (0.8–2.6)0.09
All but Lynch syndrome spectrum211,2941.16 (0.9–1.9)0.501.21 (0.5–2.4)0.33

Abbreviations: HR, hazard ratio; SIR, standardized incidence ratio; dx, diagnosis.

  • aNumber of cancers of each type observed in 16,038 person-years in family members of RINT1 probands and 914,178 person-years of observations in family members of wild-type probands.

  • bSee text for definition.